Global Tumor Biomarker Test Kits Market Research Report Segmented By Tumor Detection (Lung, Breast, Ovarian, Liver, Stomach, Prostate, Others); By Type (Protein, Genetic, Others); By Application (Diagnostic, Research Institutes, Pharmaceutical Companies); By Technology (Immunoassay, Imaging, Omics, Others); Region Forecast 2024 - 2030

Market Size and Overview:

The global Tumor Biomarker Test Kits Market is estimated to be worth USD 14.51 Billion in 2023 and is projected to reach the value of USD 29.75 Billion in 2030 growing at the CAGR of 10.8% during the forecast period 2024 – 2030.

A biomarker, also known as a biological marker, serves as an indicator for measuring biological states or conditions. Biomarker testing kits are commonly employed in the detection of cancer and other diseases by examining genes, proteins, or other substances that offer insights into the disease's manifestations in different body parts. This facilitates monitoring throughout and after treatment, aiding physicians in disease tracking. The conjunction of biomarker testing with a specific treatment is often referred to as a companion diagnostic test. Precision medicine, an approach to medical care, relies significantly on biomarker testing.

The proliferation of tumors and cancer globally, coupled with advancements in scientific and technological breakthroughs, has led to an increased preference among patients for non-invasive, efficient, reliable, and cost-effective testing methods. This trend has been instrumental in the growth of the market for tumor biomarker test kits. Pharmaceutical enterprises are actively investing in the Research and Development of testing kits, thereby contributing to the anticipated expansion of the tumor biomarker test kits market in the forecast period.

Global Drivers for the Tumor Biomarker Test Kits Market:

The escalating incidence of tumors worldwide, along with the demand for effective treatment methods, is propelling the growth of the Global Tumor Biomarker Test Kits market.

Instances of tumors and cancers have reached unprecedented levels, primarily attributed to factors such as smoking, increased pollution, and poor dietary habits, making them significant contributors to global mortality. Approximately one-third of cancer-related deaths result from tobacco use, alcohol consumption, high body mass index, and insufficient physical activity. Consequently, there is a growing market for Tumor Biomarker Test Kits, as individuals seek early detection of tumor-related diseases for prompt intervention and reduced severity risks.

Increased investments by private companies also play a pivotal role in fostering the expansion of the Global Tumor Biomarker Test Kits market.

Numerous pharmaceutical companies are channeling substantial capital into the research and development of biomarker test kits, aiming to enhance the quality and efficiency of diagnostic tools. Global consumers' preference for cost-effective diagnostic and treatment methods has prompted these investments. Governments worldwide are facilitating this growth by reducing tax rates and providing subsidies to ensure affordability, particularly for crucial tests such as tumor biomarker test kits. Such factors are poised to significantly elevate the market for Global Tumor Biomarker Test Kits in the forecast period.

Global Tumor Biomarker Test Kits Market Challenges:

Despite the rising incidence of tumors and cancer worldwide, breakthroughs in scientific treatments, and advancements in biomarker testing kits, the absence of reimbursement policies for biomarker tests in developed countries remains a challenge. The high cost of diagnosis and treatment for diseases related to tumors in developing countries is restricting the market, as patients increasingly prefer low-cost detection tests. The number of patients undergoing biomarker treatment is decreasing, posing a significant obstacle to the growth of the Global Tumor Biomarker Test Kits during the forecast period.

Global Tumor Biomarker Test Kits Market Opportunities:

The swift expansion of biomarker testing services is driven by their potential to enhance the development of innovative medications and biologic products crucial for addressing the ongoing pandemic. These services encompass a variety of disease-specific biomarkers that enable quicker and more precise disease identification, thereby reducing the timeline for clinical trials in medical research and expediting the overall drug development process. Notably, these testing services find extensive application in advancing cancer treatment solutions by detecting alterations in the genetic composition of cells. The anticipated benefits of biomarker testing kits are expected to bolster the market’s growth during the forecast period.

COVID-19 Impact on Global Tumor Biomarker Test Kits Market:

The pandemic initially impeded research and developmental activities due to lockdowns and disruptions in supply chain management, but it opened a new avenue for the market. Heightened awareness of health and the demand for more efficient, cost-effective, reliable, and quick methods of diagnosis and treatment fueled the growth of the Tumor Biomarker Test Kits market. With the easing of lockdowns and a return to normalcy, research and investments in this sector have increased at a higher rate than before. Consequently, the overall effect of the COVID-19 pandemic on the Global Tumor Biomarker Test Kits Market was moderate, and the market is anticipated to exhibit significant growth in the coming future.

Global Tumor Biomarker Test Kits Market Recent Developments:

In June 2022, Nonagen Bioscience announced that its Oncuria immunoassay for bladder cancer had received CE marking. This groundbreaking Oncuria test is a multiplex urine analysis capable of quantitatively identifying 10 specific biomarkers associated with the presence of bladder cancer.

In February 2022, OncoDNA launched the OncoDEEP Solid Tumor Biomarker Test Kit, incorporating enrichment and library preparation solutions from Twist Bioscience. This kit provides laboratories with a comprehensive and reliable option for conducting in-depth next-generation sequencing (NGS) analysis on tumor samples.

In March 2023, Prestige Biopharma is currently in the process of developing a diagnostic kit specifically designed for the detection of Pancreatic Adenocarcinoma Upregulated Factor (PAUF). This unique biomarker is highly specific to tumors and is found to be overexpressed in approximately 80% of pancreatic cancer cases, demonstrating a strong association with early development and the spread of the disease. During the application of Receiver Operating Characteristic (ROC) analysis, a method used to assess the efficacy of a biomarker, PAUF exhibited a significant sensitivity rate of more than 86% when detecting pancreatic cancer.

Global Tumor Biomarker Test Kits Market Segmentation: By Tumor Detection

1. Lung
2. Breast
3. Ovarian
4. Liver
5. Stomach
6. Prostate
7. Others

The second leading cause of death globally in 2023, accounting for over 13% of all new cases diagnosed, is lung cancer and tumors. This trend is attributed to factors such as increased tobacco smoking, exposure to asbestos, certain metals, organic compounds, radiation, and air pollution. The diagnostic test kits for lung conditions dominate this segment and are anticipated to contribute to market expansion in the foreseeable future. Biomarker test kits for breast tumors exhibited substantial growth in 2022 and are expected to continue this upward trajectory during the forecast period.

Global Tumor Biomarker Test Kits Market Segmentation: By Type

1. Protein
2. Genetic
3. Others

The Protein segment dominated the global market in 2023 and is poised to maintain its position throughout the forecast period. Research in tumor treatments has extensively utilized protein biomarkers, leading to an increased market presence for this segment. Protein biomarkers, recognized for their accuracy, are commonly employed for detecting various types of tumors.

Global Tumor Biomarker Test Kits Market Segmentation: By Application

1. Diagnostic Laboratories
2. Research Institutes
3. Pharmaceutical Companies

In 2023, the pharmaceutical companies segment held the highest market share at around 45%. There is a growing interest among pharmaceutical companies in developing targeted therapies for tumors. Research institutes and diagnostic laboratories significantly contribute to market growth, fueled by increased funding for clinical research. Pharmaceutical companies are projected to maintain their dominance, while research institutes and diagnostic laboratories are expected to experience substantial growth during the forecast period.

Global Tumor Biomarker Test Kits Market Segmentation: By Technology

1. Immunoassay
2. Imaging
3. Omics
4. Others

The Omics segment dominated the market share in 2023 due to its high efficiency in early tumor diagnosis, making it a preferred choice among patients. Ongoing research, development, and investments in Omics technology are expected to further boost its market share. There is also a rising demand for Immunoassay biomarker technology, anticipated to witness significant growth in the future as an increasing number of clinical trials and drug discovery activities utilize this technology.

Global Tumor Biomarker Test Kits Market Segmentation: By Region

1. North America
2. Europe
3. Asia-Pacific
4. South America
5. Middle East & Africa

North America held more than 45% of the market share in 2023, driven by factors such as the presence of prominent market players offering biomarker testing services, an increase in disease prevalence prompting laboratory diagnostic testing, sophisticated healthcare infrastructure, and rising research and development investments from public organizations. The Asia-Pacific region is expected to witness one of the fastest growth rates during the forecast period.

Global Tumor Biomarker Test Kits Market Key Players:

1. Prestige Biopharma
2. Bio Agilytix Labs
3. Euro fins Scientific
4. SGS SA
5. OncoDEEP
6. ICON Plc
7. IQVIA
8. Syneos Health
9. Nonagen Bioscience
10. Intertek Group